Vor Adds RemeGen RC298 to Autoimmune License

Vor Bio and China-based RemeGen amended their existing telitacicept license on November 12 to add RC298, a preclinical long-acting BAFF/APRIL inhibitor, for exclusive development and commercialization outside Greater China.




